← Leaderboards
Douglas A Drossman
University Of North Carolina Chapel Hill
$8,090,089
Attributed
$8,090,089
Total exposure
16
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $37.3K · FY2007–08$50K$37.5K$25K$12.5K$0
'07
'08
Funding mix
By agency
NIH$8,090,089 · 16
By mechanism
M01$6,545,618 · 15
R01$1,544,471 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Josephine M. Johns$7,031,584
- Sara J. Ward$5,152,771
- Edward R Perl$2,483,006
- Alan R Light$4,481,045
- Karen M Grewen$12,364,787
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationClinical ResearchGastrointestinal Disorder ChemotherapyDrug Screening /EvaluationIrritable Bowel SyndromeSerotonin InhibitorGastrointestinal AgentsFemaleDosagePlacebosGastrointestinal Sign /SymptomQuality Of LifePainBehavioral /Social Science Research TagPsychopharmacologyAnxietyPyridoindoleHealth Services Research TagHealth Care Service UtilizationDrug /AgentAudiometryElectrocardiographyChemotherapy
Grant awards (61)
EFFECT OF LOW CARBOHYDRATE DIET ON SYMPTOMS OF IBS: A PROSPECTIVE PILOT STUDY$6,581
M01 · FY2008 · RR · contact PI
PREVALENCE OF EGG ABNORMALITIES IN THE FUNCTIONAL GI DISORDERS$306
M01 · FY2008 · RR · contact PI
EFFECT OF LOW CARBOHYDRATE DIET ON SYMPTOMS OF IBS: A PROSPECTIVE PILOT STUDY$35,828
M01 · FY2007 · RR · contact PI
PREVALENCE OF EGG ABNORMALITIES IN THE FUNCTIONAL GI DISORDERS$1,501
M01 · FY2007 · RR · contact PI
Dexloxiglumide 200 mg TID in Female Patients with Constipation-Predom IBS$283
M01 · FY2004 · RR
CLINICAL TRIAL OF OPC 12759 FOR TREATMENT OF NON ULCER DYSPEPSIA$190,747
M01 · FY2002 · RR
SB 207266 A W/PLACEBO IN TREATMENT OF IRRITABLE BOWEL SYNDROME$190,747
M01 · FY2002 · RR
ALOSETRON FOR ANXIETY IN FEMALES W/ IRRITABLE BOWEL SYNDROME$190,747
M01 · FY2002 · RR
LONG TERM USE OF ALOSETRON IN SUBJECTS W/ IRRITABLE BOWEL SYNDROME$190,747
M01 · FY2002 · RR
MULTICENTER TRIAL OF FUNCTIONAL BOWEL DISORDERS$190,747
M01 · FY2002 · RR
STUDY OF CONTROLLED RELEASE DARIFENACINE IN TREATMENT OF IBS$190,747
M01 · FY2002 · RR
ALOSETRON IN FEMALE SUBJECTS W/ IRRITABLE BOWEL SYNDROME$190,747
M01 · FY2002 · RR
MULTICENTER TRIAL OF FUNCTIONAL BOWEL DISORDERS$666,850
R01 · FY2001 · DK
ALOSETRON IN FEMALE SUBJECTS W/ IRRITABLE BOWEL SYNDROME$294,555
M01 · FY2001 · RR
CLINICAL TRIAL OF OPC 12759 FOR TREATMENT OF NON ULCER DYSPEPSIA$294,555
M01 · FY2001 · RR
LONG TERM USE OF ALOSETRON IN SUBJECTS W/ IRRITABLE BOWEL SYNDROME$294,555
M01 · FY2001 · RR
SB 207266 A W/PLACEBO IN TREATMENT OF IRRITABLE BOWEL SYNDROME$294,555
M01 · FY2001 · RR
ALOSETRON FOR ANXIETY IN FEMALES W/ IRRITABLE BOWEL SYNDROME$294,555
M01 · FY2001 · RR
MULTICENTER TRIAL OF FUNCTIONAL BOWEL DISORDERS$294,555
M01 · FY2001 · RR
STUDY OF CONTROLLED RELEASE DARIFENACINE IN TREATMENT OF IBS$294,555
M01 · FY2001 · RR
LONG TERM USE OF ALOSETRON IN SUBJECTS W/ IRRITABLE BOWEL SYNDROME$190,747
M01 · FY2001 · RR
ALOSETRON IN FEMALE SUBJECTS W/ IRRITABLE BOWEL SYNDROME$190,747
M01 · FY2001 · RR
MULTICENTER TRIAL OF FUNCTIONAL BOWEL DISORDERS$190,747
M01 · FY2001 · RR
STUDY OF CONTROLLED RELEASE DARIFENACINE IN TREATMENT OF IBS$190,747
M01 · FY2001 · RR
CLINICAL TRIAL OF OPC 12759 FOR TREATMENT OF NON ULCER DYSPEPSIA$190,747
M01 · FY2001 · RR
ALOSETRON FOR ANXIETY IN FEMALES W/ IRRITABLE BOWEL SYNDROME$190,747
M01 · FY2001 · RR
SB 207266 A W/PLACEBO IN TREATMENT OF IRRITABLE BOWEL SYNDROME$190,747
M01 · FY2001 · RR
MULTICENTER TRIAL OF FUNCTIONAL BOWEL DISORDERS$877,621
R01 · FY2000 · DK
ALOSETRON IN FEMALE SUBJECTS W/ IRRITABLE BOWEL SYNDROME$294,555
M01 · FY2000 · RR
ALOSETRON IN FEMALE SUBJECTS W/ IRRITABLE BOWEL SYNDROME$294,555
M01 · FY2000 · RR
STUDY OF CONTROLLED RELEASE DARIFENACINE IN TREATMENT OF IBS$294,555
M01 · FY2000 · RR
STUDY OF CONTROLLED RELEASE DARIFENACINE IN TREATMENT OF IBS$294,555
M01 · FY2000 · RR
STUDY OF CONTROLLED RELEASE DARIFENACINE IN TREATMENT OF IBS$294,555
M01 · FY2000 · RR
ALOSETRON IN FEMALE SUBJECTS W/ IRRITABLE BOWEL SYNDROME$294,555
M01 · FY2000 · RR
ALOSETRON FOR ANXIETY IN FEMALES W/ IRRITABLE BOWEL SYNDROME$241
M01 · FY2000 · RR
SB 207266 A W/PLACEBO IN TREATMENT OF IRRITABLE BOWEL SYNDROME$241
M01 · FY2000 · RR
STUDY OF CONTROLLED RELEASE DARIFENACINE IN TREATMENT OF IBS$241
M01 · FY2000 · RR
ALOSETRON IN FEMALE SUBJECTS W/ IRRITABLE BOWEL SYNDROME$241
M01 · FY2000 · RR
CLINICAL TRIAL OF OPC 12759 FOR TREATMENT OF NON ULCER DYSPEPSIA$241
M01 · FY2000 · RR
LONG TERM USE OF ALOSETRON IN SUBJECTS W/ IRRITABLE BOWEL SYNDROME$241
M01 · FY2000 · RR
ALOSETRON IN SUBJECTS WITH NON-ULCER DYSPEPSIA$0
M01 · FY2000 · RR
CLINICAL TRIAL OF OPC 12759 FOR TREATMENT OF NON ULCER DYSPEPSIA$0
M01 · FY2000 · RR
CLINICAL TRIAL OF OPC 12759 FOR TREATMENT OF NON ULCER DYSPEPSIA$0
M01 · FY2000 · RR
CLINICAL TRIAL OF OPC 12759 FOR TREATMENT OF NON ULCER DYSPEPSIA$0
M01 · FY2000 · RR
LONG TERM USE OF ALOSETRON IN SUBJECTS W/ IRRITABLE BOWEL SYNDROME$0
M01 · FY2000 · RR
LONG TERM USE OF ALOSETRON IN SUBJECTS W/ IRRITABLE BOWEL SYNDROME$0
M01 · FY2000 · RR
LONG TERM USE OF ALOSETRON IN SUBJECTS W/ IRRITABLE BOWEL SYNDROME$0
M01 · FY2000 · RR
SB 207266 A W/PLACEBO IN TREATMENT OF IRRITABLE BOWEL SYNDROME$0
M01 · FY2000 · RR
SB 207266 A W/PLACEBO IN TREATMENT OF IRRITABLE BOWEL SYNDROME$0
M01 · FY2000 · RR
SB 207266 A W/PLACEBO IN TREATMENT OF IRRITABLE BOWEL SYNDROME$0
M01 · FY2000 · RR
ALOSETRON FOR ANXIETY IN FEMALES W/ IRRITABLE BOWEL SYNDROME$0
M01 · FY2000 · RR
ALOSETRON FOR ANXIETY IN FEMALES W/ IRRITABLE BOWEL SYNDROME$0
M01 · FY2000 · RR
ALOSETRON FOR ANXIETY IN FEMALES W/ IRRITABLE BOWEL SYNDROME$0
M01 · FY2000 · RR
SB-207266-A IN IRRITABLE BOWEL SYNDROME W/ HIV INFECTION$0
M01 · FY2000 · RR
CILANSETRON IN NON-CONSTIPATED PTS W/ IRRITABLE BOWEL SYNDROME$0
M01 · FY2000 · RR
CILANSETRON IN NON-CONSTIPATED PTS W/ IRRITABLE BOWEL SYNDROME$0
M01 · FY2000 · RR
CILANSETRON IN NON-CONSTIPATED PTS W/ IRRITABLE BOWEL SYNDROME$0
M01 · FY2000 · RR
ALOSETRON IN SUBJECTS WITH NON-ULCER DYSPEPSIA$0
M01 · FY2000 · RR
MULTICENTER TRIAL OF FUNCTIONAL BOWEL DISORDERS$0
M01 · FY2000 · RR
ALOSETRON IN SUBJECTS WITH NON-ULCER DYSPEPSIA$0
M01 · FY2000 · RR
ALOSETRON IN SUBJECTS WITH NON-ULCER DYSPEPSIA$0
M01 · FY2000 · RR